From NASDAQ: 2025-03-31 18:55:00

Vivos Therapeutics, Inc. (VVOS) reported a quarterly loss of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.43. The company showed a 34.88% earnings surprise and missed revenue estimates with $3.7 million in revenue for December 2024.

The stock price for Vivos Therapeutics has dropped 27.5% this year. The company’s earnings outlook and future performance will depend on management’s commentary and earnings call insights. Vivos Therapeutics is currently ranked #3 (Hold) on the Zacks Rank.

Lyra Therapeutics, Inc. (LYRA) is expected to report a quarterly loss of $0.15 per share, a 57.1% increase from last year. Revenue estimates for Lyra are down 54.7% from the previous year. Investors are advised to track earnings estimate revisions and industry trends for both Vivos and Lyra Therapeutics.

For more investment insights and stock recommendations, investors can access the Zacks Investment Research report on the 7 best stocks to buy for the next 30 days. The Zacks Rank stock-rating system has consistently outperformed the S&P 500, providing valuable tools and research for investors since 1978.



Read more at NASDAQ: Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates